The Postpartum Depression Patient Journey

Postpartum Depression (PPD) Supplements

A series of articles on the patient journey and management challenges of PPD

The Postpartum Depression (PPD) Patient Journey

The first supplement in this series highlights the patient perspective in postpartum depression (PPD) from the perinatal period to treatment pathways. This supplement details how PPD is the most common complication of pregnancy and childbirth,1-5 with the identification of key risk factors described, as well as common challenges related to timely diagnosis and available treatment. To support this supplement, interviews were conducted with patients who experienced PPD during the prenatal and postpartum periods. Their insights are included throughout the supplement. The objectives of this supplement are to highlight the many perspectives of women affected by PPD, help to reduce the stigma around the disorder, and advocate that women affected by PPD have access to appropriate clinical care.

 

The Postpartum Depression (PPD) Patient Journey: The Provider Perspective

The second supplement in this series highlights the provider perspective in PPD from prenatal through the postpartum period, including reviewing the importance of screening and treating patients in a timely manner. This supplement illustrates the important role that the obstetrician-gynecologist (OB-GYN) can play in screening, diagnosing, and treating this patient population. Interviews were conducted among healthcare providers who specialize in the diagnosis and treatment of patients with PPD and their insights are included throughout the supplement. One of the goals of this supplement is to highlight the importance of early detection and intervention during the postpartum period and advocate that women affected by PPD have access to appropriate clinical care.

 

The Postpartum Depression (PPD) Patient Journey: Payer Considerations

The third and final supplement in this series highlights payer considerations in PPD from prenatal through the postpartum period. This supplement reviews the importance of diagnosing and treating patients with PPD; the state- and plan-level PPD screening recommendations, policies, and programs; and the current PPD care paradigm. To support the research presented in this supplement, interviews were conducted among healthcare providers and patients with PPD, and their insights are included throughout the supplement. One of the goals of this supplement is to highlight payer considerations that may help support timely screening, clinical assessment, and, when appropriate, treatment for PPD.

 

Please complete this form, then click submit.

References: 1. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis. 2014;11:E104. 2. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9(55):1-10. 3. Ko JY, Rockhill KM, Tong VT, et al. Trends in postpartum depressive symptoms—27 states, 2004, 2008, and 2012. MMWR. 2017;66(6):153-158. https://www.cdc.gov/mmwr​/volumes/66/wr​/mm6606a1.htm. Accessed June 15, 2018. 4. Reddy UM, Rice MM, Grobman WA, et al. Serious maternal complications after early preterm delivery (24-33 weeks’ gestation). Am J Obstet Gynecol. 2015;213(4):538.e1-e9. 5. Centers for Disease Control and Prevention (CDC). Data on selected pregnancy complications in the United States 2017. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-complications-data.htm. Accessed June 15, 2018.

Terms and Conditions for Using this Site
© 2018 MediMedia, an ICON plc company.
All Rights Reserved.

© 2018 Sage Therapeutics, Inc. All rights reserved.
PP-US-PPD-0419 October 2018
This website is funded by Sage Therapeutics. All content is maintained by and property of Sage Therapeutics.